Compare FORM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORM | SRRK |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.2B |
| IPO Year | 2002 | 2018 |
| Metric | FORM | SRRK |
|---|---|---|
| Price | $73.24 | $48.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 18 |
| Target Price | ★ $144.70 | $70.06 |
| AVG Volume (30 Days) | ★ 1.5M | 1.5M |
| Earning Date | 10-28-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.84 | N/A |
| Revenue Next Year | $24.66 | $662.10 |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.65 | $38.69 |
| 52 Week High | $160.27 | $61.76 |
| Indicator | FORM | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 35.61 | 56.01 |
| Support Level | $69.88 | $44.88 |
| Resistance Level | $103.93 | $50.56 |
| Average True Range (ATR) | 6.86 | 2.95 |
| MACD | -0.09 | 0.48 |
| Stochastic Oscillator | 9.57 | 57.77 |
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.